Venclexta for Acute Myeloid Leukemia: every route to paying for it

The routes, in order

1. 1

   Why this drug and this condition are paired

   In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

   From the Indications and Usage text of the drug's FDA label. A label naming a condition is not a statement that the drug is approved, effective or covered for you.

   Label on openFDA, read 2026-11-10 · receipt

2. 2

   Medicare Part D: the yearly out-of-pocket threshold

   Found in our data
   CMS prints the Part D out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026).

   A benefit parameter of the standard Part D benefit. It applies to covered drugs under plan rules and is not a prediction of what you will pay. Your plan's formulary decides whether this drug is covered: check a formulary.

   CMS Table V-2, read 2026-11-08

3. 3

   Medicare negotiated price

   Not found in our data
   This drug is not in the CMS negotiated-price file we hold.
4. 4

   Manufacturer and foundation programs

   Found in our data
   • myAbbVie Assist receipt status not recorded
   • Cancer Drug Assistance (Multiple Programs) status not recorded
   • Genentech Patient Foundation receipt status not recorded

   A status is what the program's page says about taking applications, not whether you qualify. Each program has its own eligibility rules.

5. 5

   Charitable funds for Acute Myeloid Leukemia

   Found in our data
   We hold 4 funds for Acute Myeloid Leukemia: 2 open and 2 not open, read 2026-11-08. Open: Acute Myeloid Leukemia from Blood Cancer United (formerly the Leukemia and Lymphoma Society) and Acute myeloid leukemia (AML) from TotalAssist (Patient Advocate Foundation copay funds).

   Every fund, with its award level, insurance supported and source, is on the Acute Myeloid Leukemia page. A fund pays for a condition's costs, not necessarily this drug.

6. 6

   Clinical trial access

   Not found in our data
   We hold no trial listing for this ingredient.

Questions